Research map: In Vitro Activity of Imipenem-Funobactam Against Clinical Isolates of Gram-Negative Bacilli

Back to the article

Papers in this map

  1. CheckM: assessing the quality of microbial genomes recovered from isolates, single cells, and metagenomes · Donovan H. Parks · 2015 · 13424 citations · Cited by this paper
  2. Integrated Genome Mining, Bacterial Co-Culture Activation, and Peptidomic Analyses Identify Antimicrobial Peptide Candidates from South American Bacteria · 2026 · Related
  3. ResFinder 4.0 for predictions of phenotypes from genotypes · Valeria Bortolaia · 2020 · 3484 citations · Cited by this paper
  4. Exploratory Pharmacokinetic Characterization of Enrofloxacin and Ciprofloxacin in Plasma and Interstitial Fluid of Dogs: Nonlinear Mixed-Effects Modeling and PK/PD Target Attainment Analysis · 2026 · Related
  5. pplacer: linear time maximum-likelihood and Bayesian phylogenetic placement of sequences onto a fixed reference tree · Frederick A. Matsen IV · 2010 · 1153 citations · Cited by this paper
  6. Novel Therapeutic Approaches and Alternatives to Antibiotic Therapy for Drug-Resistant Intra-Abdominal Infections · 2026 · Related
  7. Gene and translation initiation site prediction in metagenomic sequences · Doug Hyatt · 2012 · 692 citations · Cited by this paper
  8. A New Antibacterial Protocol Based on Cymbopogon nardus (L.) Rendle Essential Oil and UV-C Radiation with Potential Application for Hatching Eggs · 2026 · Related
  9. Carbapenemase-Producing Organisms: A Global Scourge · Robert A. Bonomo · 2017 · 679 citations · Cited by this paper
  10. Towards Antimicrobial Formulations of Repurposed Drugs and Cationic Surfactants: Efficacy, Cytotoxicity on Human Cell Lines, and Ecotoxicity in Aquatic Models · 2026 · Related
  11. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents · Sameer S. Kadri · 2018 · 608 citations · Cited by this paper
  12. Time-Dependent Degradation of Imipenem in Aqueous Solution and Its Impact on Antibacterial Activity · 2026 · Related
  13. New β-Lactam–β-Lactamase Inhibitor Combinations · Dafna Yahav · 2020 · 524 citations · Cited by this paper
  14. Ceftazidime-Avibactam as Early Empiric Therapy for Gram-Negative Nosocomial Infections: A Risk-Stratified Empiric Use Informed by National AMR Surveillance Data 2024 · 2026 · Related
  15. Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing · Paolo Gaibani · 2022 · 125 citations · Cited by this paper
  16. Antibiotic Prescribing Among Inpatients with Ophthalmic Diagnoses: A Decade of Evidence from Two Private-Sector Indian Hospitals · 2026 · Related
  17. Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018–2022 · Mark G G Wise · 2024 · 115 citations · Cited by this paper
  18. In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program · Dee Shortridge · 2022 · 103 citations · Cited by this paper
  19. Impact of Difficult-to-Treat Resistance in Gram-negative Bacteremia on Mortality: Retrospective Analysis of Nationwide Surveillance Data · Kyungmin Huh · 2020 · 101 citations · Cited by this paper
  20. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes—Study for Monitoring Antimicrobial Resistance Trends, United States 2015–2017 · James A. Karlowsky · 2020 · 73 citations · Cited by this paper
  21. Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections · Maddalena Giannella · 2019 · 47 citations · Cited by this paper
  22. Cefiderocol “under siege”? Understanding the rise of NDM-mediated resistance to novel agents · Brenda A Warecki · 2025 · 35 citations · Cited by this paper
  23. Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals · María Fernanda Mojica · 2023 · 31 citations · Cited by this paper
  24. Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates—SMART United States 2019–21 · James A. Karlowsky · 2023 · 28 citations · Cited by this paper
  25. In vitro and in vivo activities of a novel β-lactamase inhibitor combination imipenem/XNW4107 against recent clinical Gram-negative bacilli from China · Yun Li · 2022 · 27 citations · Cited by this paper
  26. Imipenem/funobactam (formerly XNW4107) in vivo pharmacodynamics against serine carbapenemase-producing Gram-negative bacteria: a novel modelling approach for time-dependent killing · Andrew J Fratoni · 2023 · 21 citations · Cited by this paper
  27. Filling the Gaps: A Review and Update on Beta-Lactamase Inhibitor Combinations · Courtney Jackson · 2026 · 4 citations · Cited by this paper
  28. Plasma and intrapulmonary pharmacokinetics of funobactam, a novel diazabicyclooctane β-lactamase inhibitor, administered in combination with imipenem/cilastatin in healthy subjects · Keith A. Rodvold · 2026 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)